

Are Biosimilars Too Expensive for Emerging Economies?

Écrit par GBI Research
Jeudi, 14 Juin 2012 14:55 -



NEW YORK (GBI Research), 14 June 2012 - The global **market** for **biosimilar drugs** is due to come under attack from popular

generic drugs

, as governments fight to control rising healthcare expenditure, according to healthcare experts GBI Research.

The new report* states that governments in emerging economies are struggling to match the soaring demand for cheaper drugs, due to an increase in disease prevalence stemming from population growth, old age and unhealthy lifestyles.

However, the increasing awareness of biosimilars among physicians and patients could help biosimilars to gain significant market share, leading companies to consider offering reimbursements to patients for biosimilar products.

Clinical activities for biosimilars can take six to eight years — a time-consuming and costly process — and, while generic drug manufacturing can cost up to \$5m, biosimilar development can cost as much as \$80m–\$120m. This is primarily due to the complex structure of biological drugs, which are difficult to manufacture, and the high number of patients required for trials to prove efficacy and safety.

The possibility of failure in the biosimilars development process is also significant, and even obtaining marketing authorization for biosimilars is an extensive and difficult process. As a result, only a small number of companies can afford to enter the biosimilars market.

Patients can save around 30% through buying biosimilars rather than the corresponding innovator products, but this is still comparatively more expensive than generic drugs, which can offer up to a 90% saving. Given that a biologic treatment for metastatic cancer can cost as much as \$200,000 per year, even a substantial reduction in the cost of treatment with biosimilars will not match the value of generics. Most patients in emerging economies pay for medicine-related costs out-of-pocket, and affordability is therefore an issue for biosimilar manufacturers.

Are Biosimilars Too Expensive for Emerging Economies?

Écrit par GBI Research
Jeudi, 14 Juin 2012 14:55 -

The biosimilars market in emerging economies was valued at \$0.3 billion in 2002 and grew to a value of \$3.3 billion in 2010 at a Compound Annual Growth Rate (CAGR) of 34%. It is forecast to grow further at a CAGR of 12% from 2010 to 2018, reaching \$8 billion by 2018 at a CAGR of 12%.

* [Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production](#)

This report provides key data, information and analysis of the major trends and issues that affect the emerging biosimilars market. The report provides a comprehensive insight into the biosimilars market, with regional market forecasts for biosimilars in India and China, and analysis of the drivers and restraints that affect the market. The report looks at key market companies in the emerging biosimilars industry through profiles and analysis of their strengths, weaknesses, opportunities and threats. The report also provides information on the global biosimilars pipeline. Also discussed in detail are success factors for the emerging biosimilar industry and the regulatory environment in emerging markets with respect to biosimilars. At the end, the report provides an analysis on major deals that have taken place in the industry from 2007 to 2011.

This report was built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.